Literature DB >> 21957302

Creation of a nonspreading Rift Valley fever virus.

Jeroen Kortekaas1, Nadia Oreshkova, Viviana Cobos-Jiménez, Rianka P M Vloet, Christiaan A Potgieter, Rob J M Moormann.   

Abstract

Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic bunyavirus of the genus Phlebovirus and a serious human and veterinary pathogen. RVFV contains a three-segmented RNA genome, which is comprised of the large (L), medium (M), and small (S) segments. The proteins that are essential for genome replication are encoded by the L and S segments, whereas the structural glycoproteins are encoded by the M segment. We have produced BHK replicon cell lines (BHK-Rep) that maintain replicating L and S genome segments. Transfection of BHK-Rep cells with a plasmid encoding the structural glycoproteins results in the efficient production of RVFV replicon particles (RRPs). To facilitate monitoring of infection, the NSs gene was replaced with an enhanced green fluorescent protein gene. RRPs are infectious for both mammalian and insect cells but are incapable of autonomous spreading, rendering their application outside biosafety containment completely safe. We demonstrate that a single intramuscular vaccination with RRPs protects mice from a lethal dose of RVFV and show that RRPs can be used for rapid virus neutralization tests that do not require biocontainment facilities. The methods reported here will greatly facilitate vaccine and drug development as well as fundamental studies on RVFV biology. Moreover, it may be possible to develop similar systems for other members of the bunyavirus family as well.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21957302      PMCID: PMC3209391          DOI: 10.1128/JVI.00841-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Efficient bunyavirus rescue from cloned cDNA.

Authors:  Anice C Lowen; Carol Noonan; Angela McLees; Richard M Elliott
Journal:  Virology       Date:  2004-12-20       Impact factor: 3.616

2.  Complete genome analysis of 33 ecologically and biologically diverse Rift Valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry.

Authors:  Brian H Bird; Marina L Khristova; Pierre E Rollin; Thomas G Ksiazek; Stuart T Nichol
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

3.  T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus.

Authors:  Matthias Habjan; Nicola Penski; Martin Spiegel; Friedemann Weber
Journal:  J Gen Virol       Date:  2008-09       Impact factor: 3.891

4.  Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene.

Authors:  Tetsuro Ikegami; Sungyong Won; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge.

Authors:  Hani Boshra; Gema Lorenzo; Fernando Rodriguez; Alejandro Brun
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

6.  Crimean-Congo hemorrhagic fever virus glycoprotein processing by the endoprotease SKI-1/S1P is critical for virus infectivity.

Authors:  Eric Bergeron; Martin J Vincent; Stuart T Nichol
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

7.  Potential vectors of Rift Valley fever virus in the Mediterranean region.

Authors:  Sara Moutailler; Ghazi Krida; Francis Schaffner; Marie Vazeille; Anna-Bella Failloux
Journal:  Vector Borne Zoonotic Dis       Date:  2008-12       Impact factor: 2.133

8.  NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis.

Authors:  Sungyong Won; Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease.

Authors:  Brian H Bird; César G Albariño; Stuart T Nichol
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

10.  Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins.

Authors:  Li Liu; Cristina C P Celma; Polly Roy
Journal:  Virol J       Date:  2008-07-18       Impact factor: 4.099

View more
  44 in total

1.  A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus.

Authors:  Stephanie Devignot; Eric Bergeron; Stuart Nichol; Ali Mirazimi; Friedemann Weber
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

Review 2.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

3.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.

Authors:  Markus H Kainulainen; Jessica R Spengler; Stephen R Welch; JoAnn D Coleman-McCray; Jessica R Harmon; John D Klena; Stuart T Nichol; César G Albariño; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

5.  Heparan sulfate facilitates Rift Valley fever virus entry into the cell.

Authors:  S M de Boer; J Kortekaas; C A M de Haan; P J M Rottier; R J M Moormann; B J Bosch
Journal:  J Virol       Date:  2012-09-26       Impact factor: 5.103

Review 6.  Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.

Authors:  Kaori Terasaki; Breanna R Tercero; Shinji Makino
Journal:  Virus Res       Date:  2015-05-27       Impact factor: 3.303

7.  Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein.

Authors:  S M de Boer; J Kortekaas; L Spel; P J M Rottier; R J M Moormann; B J Bosch
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling.

Authors:  Michaela Weber; Ali Gawanbacht; Matthias Habjan; Andreas Rang; Christoph Borner; Anna Mareike Schmidt; Sophie Veitinger; Ralf Jacob; Stéphanie Devignot; Georg Kochs; Adolfo García-Sastre; Friedemann Weber
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

9.  Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Authors:  Kimberly A Dodd; Anita K McElroy; Megan E B Jones; Stuart T Nichol; Christina F Spiropoulou
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.